OverviewSuggest Edit

AxoGen is a biotech company developing treatment options for the reconstruction and repair of peripheral nerve injuries. It is passionate about restoring nerve function and quality of life to patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body.
AxoGen's portfolio of products includes Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves, AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments and Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that may be used as a soft tissue covering to reduce inflammation and scar tissue formation. 

TypePublic
Founded2002
HQAlachua, FL, US
Websiteaxogeninc.com
Employee Ratings3.5

Latest Updates

Employees (est.) (Dec 2019)371(+34%)
Job Openings25
Revenue (FY, 2020)$112.3 M(+6%)
Share Price (Oct 2021)$13.7(-1%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at AxoGen

Peter J. Mariani

Peter J. Mariani

Chief Financial Officer
Amy Wendell

Amy Wendell

Lead Director
Brad Ottinger

Brad Ottinger

General Counsel and Chief Compliance Officer
Quentin S. Blackford

Quentin S. Blackford

Director
Eric A. Sandberg

Eric A. Sandberg

Chief Commercial Officer
Gregory G. Freitag

Gregory G. Freitag

Special Counsel
Show more

AxoGen Office Locations

AxoGen has offices in Alachua and Burleson
Alachua, FL, US (HQ)
13631 Progress Blvd #400
Burleson, TX, US
300 Boone Rd
Show all (2)

AxoGen Financials and Metrics

AxoGen Revenue

Embed Graph
View revenue for all periods
AxoGen's revenue was reported to be $112.3 m in FY, 2020
USD

Revenue (Q2, 2021)

33.6m

Gross profit (Q2, 2021)

26.5m

Gross profit margin (Q2, 2021), %

78.9%

Net income (Q2, 2021)

(7.9m)

EBIT (Q2, 2021)

(7.2m)

Market capitalization (14-Oct-2021)

561.7m

Closing stock price (14-Oct-2021)

13.7

Cash (30-Jun-2021)

53.1m

EV

556.5m
AxoGen's current market capitalization is $561.7 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

4.8m7.7m10.9m16.8m27.3m41.1m60.4m83.9m106.7m112.3m

Revenue growth, %

54%63%50%

Cost of goods sold

2.4m2.0m2.4m3.4m4.8m6.5m9.3m12.9m17.3m21.6m

Gross profit

2.4m5.7m8.5m13.4m22.5m34.6m51.1m71.0m89.4m90.7m
USDQ2, 2011

Financial Leverage

1.1 x
Show all financial metrics

AxoGen Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

AxoGen Online and Social Media Presence

Embed Graph

AxoGen News and Updates

Axogen, Inc. to Report Third Quarter Financial Results and Host Conference Call on November 3, 2021

ALACHUA, Fla. and TAMPA, Fla., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report third quarter 2021 financial results on Wednes…

Axogen to Participate in the 76th Annual Meeting of the American Society for Surgery of the Hand

Industry leading nerve repair surgeons will share best practices and case studies during symposium session Industry leading nerve repair surgeons will share best practices and case studies during symposium session

Axogen RECON(SM) Clinical Study Completes Subject Follow-up

RECON is a pivotal study supporting the Company’s Biologics License Application (BLA) for Avance® Nerve Graft RECON is a pivotal study supporting the Company’s Biologics License Application (BLA) for Avance® Nerve Graft

Axogen, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference

ALACHUA, Fla. and TAMPA, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president will present at…

Axogen, Inc. Appoints John H. Johnson to Board of Directors

Global leader brings 30+ years of biopharma experience to Axogen, Inc. Board of Directors Global leader brings 30+ years of biopharma experience to Axogen, Inc. Board of Directors

Axogen, Inc. to Report Second Quarter Financial Results and Host Conference Call on August 4, 2021

ALACHUA, Fla. and TAMPA, Fla., July 14, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report second quarter 2021 financial results on Wedne…
Show more

AxoGen Blogs

repair of 5 cm median and ulnar nerve gaps after circular saw injury

A 65-year-old male presented with a complex laceration after circular saw injury. Author or contributor: Case courtesy of Dr. Bauback Safa The Buncke Clinic The post repair of 5 cm median and ulnar nerve gaps after circular saw injury first appeared on axogen.

repair of 3 cm high ulnar nerve transection

A 26-year-old male sustained lacerations to his upper arm and forearm after falling through a glass window. Author or contributor: Case courtesy of Dr. Bauback Safa The Buncke Clinic The post repair of 3 cm high ulnar nerve transection first appeared on axogen.

Axogen, Inc. to Participate at Jefferies Virtual London Healthcare Conference and Canaccord Genuity Virtual MedTech & Diagnostics Forum

ALACHUA, Fla., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at two upcoming inv…

Axogen, Inc. Reports Third Quarter 2020 Financial Results

ALACHUA, Fla., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter ended September 30, 2020. Third Quarte…

Axogen, Inc. Appoints Paul G. Thomas to Board of Directors

Healthcare veteran brings 30+ years of medtech experience to Axogen, Inc. Board of Directors ALACHUA, Fla., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves…

Axogen, Inc. Reports Second Quarter 2020 Financial Results

ALACHUA, Fla., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June 30, 2020. Second Quarte…
Show more

AxoGen Frequently Asked Questions

  • When was AxoGen founded?

    AxoGen was founded in 2002.

  • Who are AxoGen key executives?

    AxoGen's key executives are Peter J. Mariani, Amy Wendell and Brad Ottinger.

  • How many employees does AxoGen have?

    AxoGen has 371 employees.

  • What is AxoGen revenue?

    Latest AxoGen annual revenue is $112.3 m.

  • What is AxoGen revenue per employee?

    Latest AxoGen revenue per employee is $302.7 k.

  • Who are AxoGen competitors?

    Competitors of AxoGen include Promed, Sterigenics and Beckman Coulter Life Sciences.

  • Where is AxoGen headquarters?

    AxoGen headquarters is located at 13631 Progress Blvd #400, Alachua.

  • Where are AxoGen offices?

    AxoGen has offices in Alachua and Burleson.

  • How many offices does AxoGen have?

    AxoGen has 2 offices.